Novavax (NVAX) Notes Payables (2010 - 2022)

Novavax (NVAX) posted quarterly Notes Payables of $324.9 million for Q4 2022, little changed quarter-over-quarter from $324.5 million in Q3 2022.

Novavax (NVAX) Notes Payables (2010 - 2022) Analysis & Trends

Novavax's Notes Payables history runs 8 years deep, the most recent figure standing at $324.9 million for Q4 2022.

In Q4 2022, Notes Payables changed N/A year-over-year to $324.9 million; the TTM figure through Dec 2022 stood at $324.9 million (changed N/A YoY), while the FY2022 annual figure was $324.9 million, changed N/A from the prior year.
Notes Payables for Q4 2022 stood at $324.9 million, roughly flat from $324.5 million in the prior quarter.
The five-year high for Notes Payables was $324.9 million in Q4 2022, with the low at $323.8 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Novavax	1.33 Bn	607.37 Mn	42.45 Mn

Download Data